Oded Kopper
Overview
Explore the profile of Oded Kopper including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
1919
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cashman R, Haim-Abadi G, Lezmi E, Philip H, Nissenbaum J, Viner-Breuer R, et al.
Cell Prolif
. 2025 Jan;
e13788.
PMID: 39814695
Synthetic lethality is defined as a type of genetic interaction where the combination of two genetic events results in cell death, whereas each of them separately does not. Synthetic lethality...
2.
Nissenbaum J, Segal E, Philip H, Cashman R, Golan-Lev T, Reubinoff B, et al.
Cell Prolif
. 2024 Nov;
58(3):e13771.
PMID: 39523021
Taxanes and platinum molecules, specifically paclitaxel and carboplatin, are widely used anticancer drugs that induce cell death and serve as first-line chemotherapy for various cancer types. Despite the efficient effect...
3.
He A, Tian S, Kopper O, Horan D, Chen P, Bronson R, et al.
PLoS Biol
. 2023 Nov;
21(11):e3002353.
PMID: 37943878
Wnt signaling pathways are transmitted via 10 homologous frizzled receptors (FZD1-10) in humans. Reagents broadly inhibiting Wnt signaling pathways reduce growth and metastasis of many tumors, but their therapeutic development...
4.
Segal E, Nissenbaum J, Peretz M, Golan-Lev T, Cashman R, Philip H, et al.
Cell Prolif
. 2023 Apr;
56(6):e13475.
PMID: 37086010
Anticancer drugs are at the frontline of cancer therapy. However, innate resistance to these drugs occurs in one-third to one-half of patients, exposing them to the side effects of these...
5.
Dekkers J, Alieva M, Cleven A, Keramati F, Wezenaar A, van Vliet E, et al.
Nat Biotechnol
. 2022 Jul;
41(1):60-69.
PMID: 35879361
Extending the success of cellular immunotherapies against blood cancers to the realm of solid tumors will require improved in vitro models that reveal therapeutic modes of action at the molecular...
6.
Dekkers J, van Vliet E, Sachs N, Rosenbluth J, Kopper O, Rebel H, et al.
Nat Protoc
. 2021 Mar;
16(4):1936-1965.
PMID: 33692550
Organoid technology has revolutionized the study of human organ development, disease and therapy response tailored to the individual. Although detailed protocols are available for the generation and long-term propagation of...
7.
Tanaka N, Kanatani S, Kaczynska D, Fukumoto K, Louhivuori L, Mizutani T, et al.
Nat Biomed Eng
. 2020 Jul;
4(9):875-888.
PMID: 32601394
Microscopy analysis of tumour samples is commonly performed on fixed, thinly sectioned and protein-labelled tissues. However, these examinations do not reveal the intricate three-dimensional structures of tumours, nor enable the...
8.
de Witte C, Espejo Valle-Inclan J, Hami N, Lohmussaar K, Kopper O, Vreuls C, et al.
Cell Rep
. 2020 Jun;
31(11):107762.
PMID: 32553164
There remains an unmet need for preclinical models to enable personalized therapy for ovarian cancer (OC) patients. Here we evaluate the capacity of patient-derived organoids (PDOs) to predict clinical drug...
9.
Lohmussaar K, Kopper O, Korving J, Begthel H, Vreuls C, van Es J, et al.
Nat Commun
. 2020 May;
11(1):2660.
PMID: 32461556
High-grade serous ovarian cancer (HG-SOC)-often referred to as a "silent killer"-is the most lethal gynecological malignancy. The fallopian tube (murine oviduct) and ovarian surface epithelium (OSE) are considered the main...
10.
Kopper O, de Witte C, Lohmussaar K, Espejo Valle-Inclan J, Hami N, Kester L, et al.
Nat Med
. 2019 Apr;
25(5):838-849.
PMID: 31011202
Ovarian cancer (OC) is a heterogeneous disease usually diagnosed at a late stage. Experimental in vitro models that faithfully capture the hallmarks and tumor heterogeneity of OC are limited and...